About Jeito

The firm’s first fund dedicated to biotech and biopharmaceuticals.

Jeito Capital is a leading global investment company. Jeito was founded and directed by Dr. Rafaèle Tordjman, a hematologist and former fellow in Paris University Hospitals and research scientist at INSERM, who has been an investor in life sciences for more than 20 years.

Jeito I has raised 534 million euros.

In its first 18 months, Jeito Capital has built a solid and diverse portfolio of European biotechnology companies. Jeito has invested in French companies SparingVision, in the field of ophthalmology, and InnoSkel, in rare skeletal disorders, as well as Dutch biotech Neogene Therapeutics offering new options for solid tumors, U.K.-based Pulmocide, for severe respiratory diseases, and recently the French-Swiss Alentis Therapeutics in the treatment of fibrosis and associated cancers.


Our team

Jeito benefits from a multi-talented, integrated team with over 20 years’ experience across the entire value chain of the healthcare sector, from developing groundbreaking therapies to mastering IP strategy, achieving regulatory milestones and bringing them to market.

Our approach

Jeito Capital has a unique, investment strategy, providing significant capital and support in continuity to entrepreneurs and companies from clinical development to market access for breakthrough innovations.

Our mission

Go faster for the patient,
Further with the entrepreneur

In teams

Discover Jeito members

A multidisciplinary and multi-talented team of healthcare professionals, experienced in the entire value chain of therapeutic innovation development.